Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin-negative mutant.

The Journal of antibiotics - 1 Jul 1996

Johdo O, Yoshioka T, Naganawa H, Takeuchi T, Yoshimoto A

Abstract excerpt

Microbial conversion of beta-rhodomycinone and aklavinone using an aclarubicin-negative Streptomyces galilaeus mutant afforded new anthracycline antibiotics CG21-C and CG1-C which had a rednosyl-2-deoxyfucosyl-rhodosaminyl trisaccharide residue at C-7 of each added aglycone. They were produced only when a prolonged conversion culture took place. Because the usual conversion products containing a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Cell Division
Share to Magnetic Resonance Spectroscopy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Structure

Share to Mutation

Share to Streptomyces

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 8784429
DOI: 10.7164/antibiotics.49.669

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin-negative mutant.PMID 8784429Read ↗

Microbial glycosidation of some anthracycline antibiotics by an antibiotic-negative mutant of aclarubicin producer.Semantic proximity Read ↗

Production of new anthracycline antibiotic betaclamycin B by microbial conversion with a specific aclacinomycin-negative mutant.Semantic proximity Read ↗

A gene cluster from Streptomyces galilaeus involved in glycosylation of aclarubicin.Semantic proximity Read ↗

Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic WindowSemantic proximity Read ↗

Cytotoxic Anthracycline Metabolites from a Recombinant StreptomycesSemantic proximity Read ↗

Precursor-Directed Biosynthesis of Neoantimycin Derivatives with Selective Cytotoxicity.Semantic proximity Read ↗

Hybrid anthracyclines from a genetically engineered Streptomyces galilaeus mutant.Semantic proximity Read ↗

Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer AgentsSemantic proximity Read ↗

Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis.Semantic proximity Read ↗

[Biosynthesis of anthracycline: a new interpretation of the results for daunomycin biosynthesis].Semantic proximity Read ↗

In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach.Semantic proximity Read ↗

Production of new anthracycline antibiotics 1-hydroxy-oxaunomycin and 6-deoxyoxaunomycin by limited biosynthetic conversion using a daunorubicin-negative mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.